CRISPR Therapeutics AG vs Merck & Company, Inc. — Stock Comparison

CRSP
CRISPR Therapeutics AG
$51.63
▼ 1.36%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.2/10

Q·Score Breakdown

5.2
Bearish
Overall
6.7
Neutral
1.6
Quality
6.2
8.7
Health
7
3.5
Growth
6.2
6.8
Valuation
7.2
6.9
Sentiment
7.1
CRSP

Clean balance sheet with low leverage (0.1× debt-to-equity).

low return on equity (-30%).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $83.35 (+61.4%)
23 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

CRSP
MRK
Trailing P/E
31.5×
-12.9×
Forward P/E
11.5×
0.0%
Profit Margin
13.6%
0.0%
Gross Margin
76.6%
-30.2%
ROE
-97.6%
Revenue Growth
4.9%
Earnings Growth
1.79
Beta
0.28
Price / Book
$5.0B
Market Cap
$277.0B
$33 – $78
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →